ASCO 2020: Researchers underscore efficacy of pembrolizumab plus axitinib in treating advanced renal cell carcinoma - ecancer
By A Mystery Man Writer
Researchers at Fox Chase Cancer Center, along with an international team of investigators, have found that the use of pembrolizumab in combination with axiti
Frontiers Role of metastasectomy in the management of renal cell carcinoma
OncoAlert (@oncoalert) • Instagram photos and videos
ASCO 2020: KEYNOTE-426: Pembrolizumab plus Axitinib versus Sunitinib as First-Line Therapy for Advanced Renal Cell Carcinoma
Frontiers Role of metastasectomy in the management of renal cell carcinoma
Asco Sep 2023
ASCO 2021: Pembrolizumab (Pembro) plus Axitinib (Axi) Versus Sunitinib as First-Line Therapy for Advanced Clear Cell Renal Cell Carcinoma (ccRCC): Results from 42-Month Follow-up of KEYNOTE-426
ASCO GU 2022: Real-World Treatment Outcomes of First-Line Axitinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma in the United States
ASCO 2021: Pembrolizumab (Pembro) plus Axitinib (Axi) Versus Sunitinib as First-Line Therapy for Advanced Clear Cell Renal Cell Carcinoma (ccRCC): Results from 42-Month Follow-up of KEYNOTE-426
ASCO GU 2022: Real-World Treatment Outcomes of First-Line Axitinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma in the United States
Frontiers Role of metastasectomy in the management of renal cell carcinoma
Elizabeth Plimack Fox Chase Cancer Center - Philadelphia PA
ASCO 2021: Pembrolizumab (Pembro) plus Axitinib (Axi) Versus Sunitinib as First-Line Therapy for Advanced Clear Cell Renal Cell Carcinoma (ccRCC): Results from 42-Month Follow-up of KEYNOTE-426
Abeloff's clinical oncology [6 ed.] 9780323476744, 0323476740, 9780323568159, 0323568157
